| Literature DB >> 35162137 |
Jakub Marek Ratajczak1,2, Taras Hladun2, Bartosz Krenz2, Krzysztof Bromber2, Maciej Salagierski3, Michał Marczak1.
Abstract
Retrograde intrarenal surgery (RIRS) is an innovative and effective method of kidney stones treatment, as it had great influence on the development of endoscopy in urology. The increasing prevalence of urolithiasis together with the rapid development of endourology leads to a rise in the number of procedures related to the disease. Flexible ureteroscopy is constantly being improved, especially regarding the effectiveness and safety of the procedure. The purpose of this study is to evaluate intraoperative and early post-operative complications of RIRS in the treatment of kidney stones. A retrospective analysis of medical records was performed. A series was comprised of 207 consecutive operations performed from 2017 to 2020. Complications occurred in 19.3% (n = 40) of patients. Occurrence according to the Clavien-Dindo scale was: 11.1% for grade I, 5.8% for grade II and 2.4% for grade IV. Infectious complications included SIRS (5.3%, n = 11) and sepsis (2.4%, n = 5). Statistical analysis revealed a correlation between acute post-operative infections and positive midstream urine culture, history of chronic or recurrent urinary tract infections, and increased body mass index (BMI). Furthermore, a significant correlation was observed between pain requiring the use of opioids with BMI over 25. Consequently, history of urinary tract infections, positive pre-operative urine culture, and increased BMI are considered risk factors and require appropriate management.Entities:
Keywords: RIRS; UTI; complications; fURS; infection; kidney stone; sepsis; ureteroscopy; urolithiasis
Mesh:
Year: 2022 PMID: 35162137 PMCID: PMC8834554 DOI: 10.3390/ijerph19031114
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Study group characteristics.
| Parameters | % or SD Value | |
|---|---|---|
| Age (years) | 58 (13.7) | |
| Sex | Women 53.4% | |
| Men 46.6% | ||
| BMI (kg/m2) | 27.8 (5.5) | |
| Operation side | Left 50.7% | |
| Right 49.3% | ||
| Operation time (min) | 45 (15) | |
| Stone size (mm) | Occurrence | Size (SD) |
| Largest stone | 100% | 10 (3.9) |
| 2nd | 37.20% | 6 (2.8) |
| 3rd | 12.60% | 5 (1.9) |
| Largest stone location: | ||
| Upper calyx | 11.80% | |
| Medium calyx | 21.10% | |
| Lower calyx | 45.60% | |
| Kidney pelvis | 21.60% | |
| 2nd Largest stone location: | ||
| Upper calyx | 10.40% | |
| Medium calyx | 40.30% | |
| Lower calyx | 37.70% | |
| Kidney pelvis | 11.70% | |
| Comorbidities: | ||
| Ischemic heart disease | 8.6% ( | |
| Diabetes | 15.9% ( | |
| Recurrent/chronic UTI | 20.3% ( | |
| Chronic kidney disease | 4.3% ( | |
| Hypertension | 23.2% ( | |
| Hypothyroidism | 8.2% ( | |
| Gout | 4.8% ( | |
| Chronic obstructive pulmonary disease | 2.4% ( | |
Mid-stream urine culture results.
| Mid-Stream Urine Culture: | % ( |
|---|---|
| Total Available | 88.4% (183) |
| Negative/sterile | 67.2% (123) |
| Positive | 32.8% (60) |
| Not available | 11.6% (24) |
Figure 1Positive urine culture results.
Results and description of surgical complications according to Clavien-Dindo classification.
| Grade | Description |
| % |
|---|---|---|---|
| I | Any deviation from the normal post-operative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions. Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgesics, diuretics and electrolytes and physiotherapy. This grade also includes wound infections opened at the bedside. | 23 | 11.1 |
| II | Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Blood transfusions and total parenteral nutrition are also included. | 12 | 5.8 |
| III | Requiring surgical, endoscopic or radiological intervention. | null | null |
| IV | Life-threatening complications (including CNS complications) requiring IC/ICU-management. | 5 | 2.4 |
| V | Death of a patient. | null | null |
Parameters affecting occurrence of SIRS/sepsis.
| Level of | Odds | Lower CI | Upper CI |
| |
|---|---|---|---|---|---|
| Largest stone diameter (mm) | 0.878796 | 0.760866 | 1.01500 | 0.078850 | |
| Normal weight | BMI 18.5–25 | 2.749022 | 0.579156 | 13.04850 | 0.142517 |
| Underwieght | BMI < 18.5 | 0.216355 | 0.013141 | 3.56211 | 0.119581 |
| Overweight | BMI > 25 | 2.526093 | 0.630934 | 10.11381 | 0.148003 |
| UTI | 4.852125 | 1.308780 | 17.98860 | 0.018153 | |
| Diabetes | 2.977971 | 0.635067 | 13.96436 | 0.166329 | |
| Urine culture | Non-sterile | 0.139426 | 0.041352 | 0.47010 | 0.001487 |
Estimated variance-covariance matrix.
| Intercept | Largest Stone | BMI 18.5–25 | BMI < 18.5 | BMI > 25 | History of Infection | Diabetes | Positive Urine Culture | |
|---|---|---|---|---|---|---|---|---|
| Intercept | 0.980160 | −0.062800 | −0.001948 | 0.316145 | −0.118121 | 0.045744 | −0.024435 | −0.008929 |
| Largest stone diameter (mm) | −0.062800 | 0.005405 | −0.004559 | −0.000998 | 0.001139 | −0.008407 | −0.006558 | 0.000237 |
| BMI 18.5–25 | −0.001948 | −0.004559 | 0.384616 | −0.394674 | −0.003049 | 0.021113 | −0.015871 | −0.022897 |
| BMI < 18.5 | 0.316145 | −0.000998 | −0.394674 | 1.100130 | −0.370720 | −0.043936 | −0.018200 | 0.030884 |
| BMI > 25 | −0.118121 | 0.001139 | −0.003049 | −0.370720 | 0.325158 | 0.012591 | 0.016305 | −0.021175 |
| History of infection | 0.045744 | −0.008407 | 0.021113 | −0.043936 | 0.012591 | 0.111738 | 0.043180 | −0.010176 |
| Diabetes | −0.024435 | −0.006558 | −0.015871 | −0.018200 | 0.016305 | 0.043180 | 0.155400 | −0.017252 |
| Positive urine culture | −0.008929 | 0.000237 | −0.022897 | 0.030884 | −0.021175 | −0.010176 | −0.017252 | 0.096138 |
Estimated correlation matrix.
| Intercept | Largest Stone Diameter (mm) | BMI 18.5–25 | BMI < 18.5 | BMI > 25 | History of Infection | Diabetes | Positive Urine Culture | |
|---|---|---|---|---|---|---|---|---|
| Intercept | 1.000000 | −0.862795 | −0.003173 | 0.304449 | −0.209234 | 0.138224 | −0.062608 | −0.029089 |
| Largest stone diameter (mm) | −0.862795 | 1.000000 | −0.099989 | −0.012945 | 0.027170 | −0.342084 | −0.226265 | 0.010375 |
| BMI 18.5–25 | −0.003173 | −0.099989 | 1.000000 | −0.606740 | −0.008621 | 0.101843 | −0.064918 | −0.119077 |
| BMI < 18.5 | 0.304449 | −0.012945 | −0.606740 | 1.000000 | −0.619836 | −0.125313 | −0.044017 | 0.094964 |
| BMI > 25 | −0.209234 | 0.027170 | −0.008621 | −0.619836 | 1.000000 | 0.066057 | 0.072534 | −0.119763 |
| History of infection | 0.138224 | −0.342084 | 0.101843 | −0.125313 | 0.066057 | 1.000000 | 0.327683 | −0.098180 |
| Diabetes | −0.062608 | −0.226265 | −0.064918 | −0.044017 | 0.072534 | 0.327683 | 1.000000 | −0.141146 |
| Positive urine culture | −0.029089 | 0.010375 | −0.119077 | 0.094964 | −0.119763 | −0.098180 | −0.141146 | 1.000000 |